Assessment of Canadian provincial expenditures in depressed patients treated with venlafaxine XR versus SSRIs: the APEX Study

References

• Andrade L, Caraveo-Anduaga JJ, Berglund P, Bijl RV, De Graaf R, Vollebergh W et al. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Methods Psychiatr Res 2003;12:3–21
   PubMed Web of Science ®Google Scholar
• Health Canada. A report on mental illnesses in Canada; Chapter 1: Mental illnesses in Canada: an overview. 2002. Ottawa (ON), Health Canada. Available from: www.phac-aspc.gc.ca/publicat/ miic-mmac/. [Last accessed 11 October 2005]
   Google Scholar
• Hirschfeld RM, Keller MB, Panico S, Arons BS, Barlow D, Davidoff F et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 1997;277:333–40
   PubMed Web of Science ®Google Scholar
• Nutting PA, Rost K, Dickinson M, Werner JJ, Dickinson P, Smith JL et al. Barriers to initiating depression treatment in primary care practice. J Gen Intern Med 2002;17:103–11
   PubMed Web of Science ®Google Scholar
• Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997; 349:1498–1504
   PubMed Web of Science ®Google Scholar
• Parikh SV, Lam RW. Clinical guidelines for the treatment of depressive disorders, I. Definitions, prevalence, and health burden. Can J Psychiatry 2001;46\(Suppl 1):13S–20S
   Google Scholar
• World Health Organization. World health report 2001. Mental health: new understanding, new hope. 2001. Geneva: World Health Organization: 2001
   Google Scholar
• Stephens T, Joubert N. The economic burden of mental health problems in Canada. Chronic Dis Can 2001;22:18–23
   PubMedGoogle Scholar
• Clinical guidelines for the treatment of depressive disorders. Can J Psychiatry 2001;46 (Suppl 1):5S–90S
   Google Scholar
• Panzarino PJ, Jr, Nash DB. Cost-effective treatment of depression with selective serotonin reuptake inhibitors. Am J Manag Care 2001;7:173–84
   Google Scholar
• Wilde MI, Whittington R. Paroxetine. A pharmacoeconomic evaluation of its use in depression. Pharmacoeconomics 1995;8:62–81
   Google Scholar
• Wilde MI, Benfield P. Fluoxetine. A pharmacoeconomic review of its use in depression. Pharmacoeconomics 1998;13:543–61
   Google Scholar
• Davis R, Wilde MI. Sertraline. A pharmacoeconomic evaluation of its use in depression. Pharmacoeconomics 1996;10: 409–31
   Google Scholar
• Trivedi MH, Wan GJ, Mallick R, Chen J, Casciano R, Geissler EC et al. Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder. J Clin Psychopharmacol 2004;24:497–506
   PubMed Web of Science ®Google Scholar
• Lenox-Smith A, Conway P, Knight C. Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK. Pharmacoeconomics 2004;22:311–9
   Google Scholar
• Casciano J, Doyle J, Arikian S, Casciano R. The health economic impact of antidepressant usage from a payer’s perspective: a multinational study. Int J Clin Pract 2001;55:292–9
   PubMed Web of Science ®Google Scholar
• Wan GJ, Crown WH, Berndt ER, Finkelstein SN, Ling D. Healthcare expenditure in patients treated with venlafaxine or selective serotonin reuptake inhibitors for depression and anxiety. Int J Clin Pract 2002;56:434–9
   Google Scholar
• Crown WH, Treglia M, Meneades L, White A. Long-term costs of treatment for depression: impact of drug selection and guideline adherence. Value Health 2001;4:295–307
   PubMedGoogle Scholar
• Crown WH. Antidepressant selection and economic outcome: a review of methods and studies from clinical practice. Br J Psychiatry 2001;42(Suppl):S18–S22
   Google Scholar
• Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995;48:999–1009
   PubMed Web of Science ®Google Scholar
• Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45: 197–203
   Google Scholar
• Rahme E, Joseph L, Kong SX, Watson DJ, LeLorier J. Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients. Br J Clin Pharmacol 2001;52:185–92
   Google Scholar
• Sclar DA, Robison LM, Skaer TL, Galin RS, Legg RF, Nemec NL et al. Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization. J Int Med Res 1995;23:395–412
   PubMed Web of Science ®Google Scholar
• Sullivan EM, Griffiths RI, Frank RG, Strauss MJ, Herbert RJ, Clouse J et al. One-year costs of second-line therapies for depression. J Clin Psychiatry 2000;61:290–98
   PubMed Web of Science ®Google Scholar
• Statistics Canada. Hospital Statistics: Preliminary Annual Report, 1994–1995. Catalogue No. 83–241-XPB 1996. 1996. Ottawa, Canada, Ministry of Health, Health Statistics Division
   Google Scholar
• Association des hôpitaux du Québec. Répertoire des établissements membres de l’Association des hôpitaux du Québec: 2002–2003. 2002
   Google Scholar
• Régie de l’Assurance Maladie du Québec. Manuel des médecins omnipraticiens. Direction des services à la clientele professionnelle. Service de l’information professionnelle. 2005. Quebec, Canada, RAMQ
   Google Scholar
• Régie de l’Assurance Maladie du Québec (RAMQ). Manuel des médecins spécialistes. Direction des services à la clientele professionnelle. Service de l’information professionnelle. 2005. Québec, Canada, RAMQ
   Google Scholar
• Régie de l’Assurance Maladie du Québec (RAMQ). Liste des medicaments, 15 October 2003. Service de l’information aux professionnels, Dépôt légal – Bibliothéque nationale du Canada. 2003. Québec, Canada, RAMQ
   Google Scholar
• Ministère de la Santé et des Services Sociaux. Évaluation de la performance économique globale des centres hospitaliers de soins généraux et spécialisés, volet ‘clientèle hospitalisée’ – résultats 2002–2003. 2003. Gouvernement du Québec
   Google Scholar
• Barber J, Thompson S. Multiple regression of cost data: use of generalised linear models. J Health Serv Res Policy 2004;9: 197–204
   PubMedGoogle Scholar
• Callahan CM, Kroenke K, Counsell SR, Hendrie HC, Perkins AJ, Katon W et al. Treatment of depression improves physical functioning in older adults. J Am Geriatr Soc 2005;53:367–73
   PubMed Web of Science ®Google Scholar
• Ford JD, Trestman RL, Steinberg K, Tennen H, Allen S. Prospective association of anxiety, depressive, and addictive disorders with high utilization of primary, specialty and emergency medical care. Soc Sci Med 2004;58:2145–8
   Google Scholar
• Hunkeler EM, Spector WD, Fireman B, Rice DP, Weisner C. Psychiatric symptoms, impaired function, and medical care costs in an HMO setting. Gen Hosp Psychiatry 2003;25: 178–84
   Google Scholar
• Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther 2003;25:2289–304
   PubMed Web of Science ®Google Scholar
• Schulberg HC, Katon W, Simon GE, Rush AJ. Treating major depression in primary care practice: an update of the Agency for Health Care Policy and Research Practice Guidelines. Arch Gen Psychiatry 1998;55:1121–7
   PubMed Web of Science ®Google Scholar
• Depression Guideline Panel. Treatment of major depression. Depression in primary care: detection, diagnoses, and treatment. Vol. 2. Clinical Practice Guideline No. 5. 1993. Rockville, MD: US Dept of Health and Human Services, Public Health Service, and Agency for Health Care Policy and Research, AHCPR publication 93–0550
   Google Scholar
• Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry 2000;157(Suppl):1–45
   Google Scholar
• Maj M, Veltro F, Pirozzi R, Lobrace S, Magliano L. Pattern of recurrence of illness after recovery from an episode of major depression: a prospective study. Am J Psychiatry 1992;149: 795–800
   Google Scholar
• Sturm R, Wells KB. How can care for depression become more cost-effective? JAMA 1995;273:51–8
   PubMed Web of Science ®Google Scholar
• Katon W, Von Korff M, Lin E, Bush T, Ormel J. Adequacy and duration of antidepressant treatment in primary care. Med Care 1992;30:67–76
   PubMed Web of Science ®Google Scholar
• Simon GE, VonKorff M, Wagner EH, Barlow W. Patterns of antidepressant use in community practice. Gen Hosp Psychiatry 1993;15:399–408
   PubMed Web of Science ®Google Scholar
• Lawrenson RA, Tyrer F, Newson RB, Farmer RD. The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared. J Affect Disord 2000;59:149–157
   PubMed Web of Science ®Google Scholar
• Joffe RT, Iskedjian M, Einarson TR, O’Brien BJ, Stang MR. Examining the Saskatchewan health drug database for anti-depressant use: the case of fluoxetine. Can J Clin Pharmacol 2001;8:146–52
   Google Scholar
• Mullins CD, Shaya FT, Meng F, Wang J, Harrison D. Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram. Pharmacotherapy 2005;25:660–67
   Google Scholar
• Bull SA, Hunkeler EM, Lee JY, Rowland CR, Williamson TE, Schwab JR et al. Discontinuing or switching selective serotoninreuptake inhibitors. Ann Pharmacother 2002;36:578–84
   PubMed Web of Science ®Google Scholar
• Cardinal H, Monfared AA, Dorais M, LeLorier J. The concept of the ‘percent wasted patients’ in preventive health strategies. Pharmacoepidemiol Drug Saf 2005; doi:10.1002/ pds.1148
   Google Scholar
• Health Canada. A report on mental illnesses in Canada; Chapter 2: Mood Disorders. 2002. Ottawa (ON), Health Canada. Available at http://www.phac-aspc.gc.ca/publicat/miic-mmac/. [Accessed 2005 October 11]
   Google Scholar
• Demyttenaere K, Enzlin P, Dewe W, Boulanger B, De Bie J, De Troyer W et al. Compliance with antidepressants in a primary care setting, 1: Beyond lack of efficacy and adverse events. J Clin Psychiatry 2001;62\(Suppl 22):30–33
   Google Scholar
• Leon AC, Solomon DA, Mueller TI, Endicott J, Rice JP, Maser JD et al. A 20-year longitudinal observational study of somatic antidepressant treatment effectiveness. Am J Psychiatry 2003;160:727–33
   PubMed Web of Science ®Google Scholar
• Donoghue J, Hylan TR. Antidepressant use in clinical practice: efficacy v. effectiveness. Br J Psychiatry 2001;42(Suppl): S9–S17
   Google Scholar
• Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002;180:396–404
   Google Scholar
• Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234–41
   Google Scholar
• Wong DT, Bymaster FP. Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype? Prog Drug Res 2002;58:169–222
   PubMedGoogle Scholar
• Poret AW, Neslusan C, Ricci JF, Wang S, Khan ZM, Kwong JW. Retrospective analysis of the health-care costs of bupropion sustained release in comparison with other antidepressants. Value Health 2001;4:362–9
   PubMedGoogle Scholar
• Montgomery SA, Entsuah R, Hackett D, Kunz NR, Rudolph RL. Venlafaxine versus placebo in the preventive treatment of recurrent major depression. J Clin Psychiatry 2004;65:328–36
   Google Scholar
• Klinkman MS, Coyne JC, Gallo S, Schwenk TL. False positives, false negatives, and the validity of the diagnosis of major depression in primary care. Arch Fam Med 1998;7:51–461
   PubMedGoogle Scholar
• Olfson M, Marcus SC, Druss B, Elinson L, Tanielian T, Pincus HA. National trends in the outpatient treatment of depression. JAMA 2002;287:203–9
   PubMed Web of Science ®Google Scholar
• Jones G. Prescribing and taking medicines. BMJ 2003;327:819
   PubMed Web of Science ®Google Scholar
• Schulberg HC, Madonia MJ, Block MR, Coulehan JL, Scott CP, Rodriguez E et al. Major depression in primary care practice. Clinical characteristics and treatment implications. Psychosomatics 1995;36:129–37
   Google Scholar